The Global 0.9% Sodium Chloride Injection Market was valued at USD 13.65 Billion in 2025 and is projected to reach USD 19.84 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period (2025–2032). This growth is being driven by the rising global burden of chronic diseases, an aging population, expanding surgical volumes, and the indispensable role of this therapy in fluid resuscitation, medication delivery, and electrolyte maintenance across global healthcare systems.

As healthcare infrastructure expands and treatment protocols become more standardized, the demand for this essential medical commodity continues to surge. In this blog, we profile the Top 10 Companies in the 0.9% Sodium Chloride Injection Industry—a mix of global pharmaceutical giants, specialized injectable manufacturers, and strategic suppliers shaping the future of patient care and clinical supply chains.

---

🔟 1. Baxter International Inc.

Headquarters: Deerfield, Illinois, USA
Key Offering: Viaflex® IV Bags, Galaxy® Containers, Ready-to-Use Saline Solutions

Baxter International stands as a global titan in the hospital pharmacy and IV solutions sector. The company’s comprehensive portfolio of 0.9% Sodium Chloride injections, available in flexible bags and rigid containers, is a cornerstone of clinical care in over 100 countries. Baxter’s strength lies in its vertically integrated manufacturing, stringent quality control, and continuous innovation in drug delivery systems, making it a preferred partner for health systems worldwide.

Strategic Initiatives:

• Global expansion of sterile manufacturing capacity to meet rising demand.
• Investment in next-generation, ready-to-use packaging to enhance clinician safety and efficiency.
• Strategic focus on sustainability through optimized plastic use and reduced packaging waste.

Download FREE Sample Report: 0.9% Sodium Chloride Injection Market – View in Detailed Research Report

---

9️⃣ 2. Fresenius Kabi AG

Headquarters: Bad Homburg, Germany
Key Offering: Fresenius Kabi Saline IV Bags, Ecoflac®-plus containers, Specialty IV Therapies

Fresenius Kabi is a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Its 0.9% Sodium Chloride products are renowned for high quality and reliability, serving a vast network of hospitals, clinics, and homecare providers. The company leverages its strong European base and growing presence in emerging markets to secure its position as a leading supplier of essential injectables.

Strategic Initiatives:

• Major capacity investments in Asia and North America to de-risk supply chains.
• Development of eco-friendly packaging solutions and sustainable manufacturing processes.
• Integration of digital track-and-trace technologies for enhanced supply chain integrity.

---

8️⃣ 3. B. Braun Melsungen AG

Headquarters: Melsungen, Germany
Key Offering: Steriflex®-bag, Ecoflac®-bag, Infusomat® Space Infusion Systems

B. Braun is a leading German provider of healthcare solutions, with a deeply entrenched reputation for safety and quality in infusion therapy. The company’s 0.9% Sodium Chloride injections are integral to its “Therapy Safety” concept, designed to minimize risks throughout the medication process. B. Braun’s portfolio is distinguished by its focus on system compatibility, reducing the potential for errors in complex clinical environments.

Strategic Initiatives:

• Continuous R&D in safety-engineered drug delivery systems and smart infusion pumps.
• Expansion of production footprints in key growth regions, including the Middle East and Asia-Pacific.
• Strong emphasis on training and education for healthcare professionals on safe IV practices.

Download FREE Sample Report: 0.9% Sodium Chloride Injection Market – View in Detailed Research Report

---

7️⃣ 4. Pfizer Inc. (Hospira)

Headquarters: New York City, New York, USA
Key Offering: Hospira-brand Sodium Chloride Injections, Glass and Plastic Containers

Following its acquisition of Hospira, Pfizer solidified its position as a global leader in sterile injectable pharmaceuticals, including 0.9% Sodium Chloride. The company’s expansive portfolio serves critical needs in hospitals worldwide, from routine hydration to complex drug dilutions. Pfizer leverages its massive scale, regulatory expertise, and robust global distribution network to ensure reliable supply of this essential commodity, particularly in markets with stringent quality requirements.

Strategic Initiatives:

• Ongoing modernization and expansion of legacy Hospira manufacturing sites to increase output and reliability.
• Strategic focus on biosimilars and complex injectables, with saline as a key enabling vehicle.
• Commitment to addressing drug shortages by enhancing production capacity for essential medicines.

---

6️⃣ 5. ICU Medical, Inc.

Headquarters: San Clemente, California, USA
Key Offering: IV Solutions, ChemoLock® Vial Access Device, PCA and Syringe Infusion Systems

ICU Medical is a specialized player focused on innovative infusion therapy and critical care products. The company supplies 0.9% Sodium Chloride injections as part of comprehensive infusion systems designed to improve patient safety. Its acquisition of Pfizer’s Hospira infusion business significantly expanded its product lines and manufacturing capabilities, making it a formidable integrated player in the IV solutions and drug delivery systems market.

Strategic Initiatives:

• Integration of infusion devices with consumables (like saline bags) to create closed, safer hospital ecosystems.
• Growth through strategic acquisitions to expand geographic and product portfolio reach.
• Innovation in needle-free and closed-system transfer devices to protect healthcare workers and patients.

---

5️⃣ 6. Otsuka Pharmaceutical Factory, Inc.

Headquarters: Naruto, Tokushima, Japan
Key Offering: Otsuka Normal Saline, Large-Volume Parenteral (LVP) Solutions

Otsuka is a dominant force in the Japanese and broader Asian markets for intravenous fluids. The company is renowned for its high-quality, large-volume parenteral products, including 0.9% Sodium Chloride. Otsuka’s strength lies in its deep understanding of regional regulatory landscapes and its commitment to manufacturing excellence, making it a trusted supplier for hospitals across Asia where demand is growing rapidly.

Strategic Initiatives:

• Leadership in the high-growth Asia-Pacific IV solutions market.
• Focus on developing niche, high-value IV formulations alongside standard saline products.
• Investment in automated, high-efficiency production lines to ensure consistent supply.

---

4️⃣ 7. Sichuan Kelun Pharmaceutical Co., Ltd.

Headquarters: Chengdu, Sichuan, China
Key Offering: Standard and Specialty IV Fluids, Saline in Flexible Containers

Sichuan Kelun is one of China’s largest pharmaceutical manufacturers and a leading producer of intravenous solutions, including 0.9% Sodium Chloride. The company benefits from massive domestic demand driven by China’s healthcare expansion and is increasingly exporting to international markets. Its competitive cost structure and scalable production make it a significant and growing player in the global supply chain for essential infusions.

Strategic Initiatives:

• Rapid scale-up of production capacity to serve both the colossal Chinese market and export ambitions.
• Investment in R&D to move up the value chain into more complex injectables and biologics.
• Strategic partnerships and compliance efforts to meet stringent international quality standards (e.g., USFDA, EU GMP).

Download FREE Sample Report: 0.9% Sodium Chloride Injection Market – View in Detailed Research Report

---

3️⃣ 8. Vifor Pharma Management Ltd. (CSL Group)

Headquarters: Saint-Gall, Switzerland
Key Offering: IV Saline Solutions, Specialty Infusion Products for Nephrology and Cardiology

While Vifor Pharma is best known for its focus on iron deficiency and nephrology, its product portfolio includes essential IV fluids critical for therapeutic areas it serves. Its saline solutions are often part of specialized treatment regimens in hospital settings. Backed by the resources of parent company CSL, Vifor combines therapeutic area expertise with a high-quality manufacturing base, serving a dedicated segment of the hospital market.

Strategic Initiatives:

• Integration of IV fluids within targeted therapeutic area strategies (e.g., heart failure, kidney disease).
• Leveraging the global commercial footprint of the CSL Group for market access.
• Maintaining a focus on high-margin specialty care while supplying essential hospital commodities.

---

2️⃣ 9. B. Braun Medical Inc. (US Subsidiary)

Headquarters: Bethlehem, Pennsylvania, USA
Key Offering: Full range of IV solutions, Customized sterile compounding services

As the US arm of B. Braun Melsungen AG, this entity is a critical supplier to the vast American healthcare market. It operates state-of-the-art manufacturing facilities dedicated to producing 0.9% Sodium Chloride and other IV fluids that meet rigorous FDA standards. The company plays a vital role in national health security by providing a reliable domestic source for these essential medical products, mitigating import-related supply chain risks.

Strategic Initiatives:

• Domestic manufacturing focus to ensure supply resilience for the U.S. market.
• Provision of value-added services like premixed medications and pharmacy outsourcing solutions.
• Active participation in GPO (Group Purchasing Organization) contracts with major U.S. hospital networks.

---

1️⃣ 10. Amphastar Pharmaceuticals, Inc.

Headquarters: Rancho Cucamonga, California, USA
Key Offering: Sterile Injectables, Nebulized Products, 0.9% Sodium Chloride for Inhalation/Injection

Amphastar is a growing, diversified pharmaceutical company with a significant stake in the sterile injectables market. It manufactures 0.9% Sodium Chloride for both injection and inhalation use, catering to a range of clinical needs from IV therapy to respiratory care. The company’s nimble operations and focus on niche, high-quality manufacturing allow it to compete effectively in specific segments, often addressing supply gaps for essential medicines.

Strategic Initiatives:

• Strategic investments in expanding sterile injectable manufacturing capacity.
• Focus on 505(b)(2) regulatory pathways for specialized saline-based drug delivery systems.
• Building a robust portfolio of generic injectables to capitalize on market opportunities created by product shortages.

Get Full Report Here: 0.9% Sodium Chloride Injection Market – View in Detailed Research Report

---

🏥 Outlook: The Future of 0.9% Sodium Chloride Injection Is Smarter and More Resilient

The 0.9% Sodium Chloride Injection market is undergoing a strategic evolution. While it remains a high-volume commodity, the industry is investing heavily in supply chain resilience, advanced packaging, and integrated drug delivery systems to meet the demands of modern healthcare.

📈 Key Trends Shaping the Market:

• Accelerated regionalization of manufacturing to mitigate global supply chain vulnerabilities.
• Adoption of smart packaging with barcoding, RFID tags, and tamper-evidence for traceability and safety.
• Growing demand for ready-to-use, pre-mixed solutions to improve clinical workflow efficiency and reduce errors.
• Increasing focus on environmental sustainability, driving innovation in recyclable materials and reduced plastic waste.

Get Full Report Here: 0.9% Sodium Chloride Injection Market – View in Detailed Research Report

The companies listed above are not only supplying a foundational medical product—they are engineering the reliable, safe, and efficient infrastructure that underpins global patient care.